NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.83 +1.48 (+6.62 %)
(As of 11/15/2018 04:00 PM ET)
Previous Close$22.35
Today's Range$22.41 - $24.0250
52-Week Range$12.70 - $25.07
Volume382,436 shs
Average Volume686,948 shs
Market Capitalization$1.19 billion
P/E Ratio-68.09
Dividend YieldN/A
Beta1.06
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VNDA
Previous Symbol
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio6.03
Quick Ratio6.01

Price-To-Earnings

Trailing P/E Ratio-68.09
Forward P/E Ratio595.75
P/E Growth18.47

Sales & Book Value

Annual Sales$165.08 million
Price / Sales7.57
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book4.79

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins7.06%
Return on Equity5.88%
Return on Assets4.57%

Miscellaneous

Employees273
Outstanding Shares52,450,000
Market Cap$1.19 billion
OptionableOptionable

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. The biopharmaceutical company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) EPS. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Vanda Pharmaceuticals.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $180-200 million, compared to the consensus revenue estimate of $192.44 million.

What price target have analysts set for VNDA?

7 brokers have issued 12 month price targets for Vanda Pharmaceuticals' shares. Their predictions range from $26.00 to $31.00. On average, they expect Vanda Pharmaceuticals' stock price to reach $28.8333 in the next year. This suggests a possible upside of 21.0% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vanda Pharmaceuticals.

What are Wall Street analysts saying about Vanda Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (11/7/2018)
  • 2. Stifel Nicolaus analysts commented, "We reiterate our Buy rating and $30 target price. All relevant disclosures and certifications appear on pages 3 – 5 of this report. Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.Investment Thesis We believe Vanda’s current valuation is an attractive entry point for investors, given its accelerating base business and relatively de-risked, late-stage pipeline that we believe is under-appreciated." (10/31/2018)
  • 3. Cantor Fitzgerald analysts commented, "We are Neutral on VNDA with a 12-month PT of $26. HETLIOZ is delivering consistent growth in non-24, approaching the $100M threshold in net revs, which we view as an inflection point in broadening institutional interest. However, our Neutral rating results from the lack of visibility on the tradipitant P3 program for neuropathic itch (i.e., pruritus) in atopic dermatitis and meaningful pipeline-driven growth. Although we believe that the program has an increased PoS resulting from a P3 design well-informed by P2 data, in our view, enhanced clarity on timelines is needed to become more constructive." (10/3/2018)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Press coverage about VNDA stock has been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,165,882 shares, an increase of 89.1% from the September 28th total of 2,203,512 shares. Based on an average daily trading volume, of 805,294 shares, the days-to-cover ratio is presently 5.2 days. Currently, 8.2% of the company's stock are sold short. View Vanda Pharmaceuticals' Current Options Chain.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 52)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 49)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 52)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.89%), Macquarie Group Ltd. (5.11%), Renaissance Technologies LLC (3.91%), Glenmede Trust Co. NA (3.37%), FMR LLC (2.13%) and First Manhattan Co. (1.58%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which major investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, FMR LLC, First Manhattan Co., Alambic Investment Management L.P., Man Group plc, Prudential Financial Inc., Credit Suisse AG and BlueMountain Capital Management LLC. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which major investors are buying Vanda Pharmaceuticals stock?

VNDA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Glenmede Trust Co. NA, Wells Fargo & Company MN, Bank of New York Mellon Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Acadian Asset Management LLC and Arizona State Retirement System. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $23.83.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $1.19 billion and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is http://www.vandapharmaceuticals.com.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  613
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Featured Article: What is a Tariff?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel